Inicio › Leucemia mielógena aguda › California › Orange
Ensayos clínicos de Leucemia mielógena aguda en Orange, CA
13 estudios para Leucemia mielógena aguda buscan participantes en centros de Orange y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ReclutandoFase 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
ReclutandoFase 2
- UCI Health Chao Family Comprehensive Cancer Center, Orange
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
ReclutandoFase 3
- Children's Hospital of Orange County, Orange
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
ReclutandoFase 1/2
- Children's Hospital of Orange County, Orange
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
ReclutandoFase 1
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
ReclutandoFase 3
- Children's Hospital of Orange County Main Campus - Orange, Orange
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
ReclutandoFase 3
- University of California, Irvine, Orange
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
ReclutandoFase 1
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
ReclutandoFase 1
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
ReclutandoFase 4
- UCI Irvine Health, Orange
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ReclutandoEstudio observacional
- Children's Hospital of Orange County (CHOC), Orange
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
ReclutandoFase 2/3
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
ReclutandoFase 1
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
Más información sobre Leucemia mielógena aguda en MedlinePlus
Ensayos de Leucemia mielógena aguda en otras ciudades
- Houston, TX85 estudios
- New York City, NY51 estudios
- Boston, MA44 estudios
- Seattle, WA41 estudios
- Baldwin Park, CA40 estudios
- Columbus, OH35 estudios
- Philadelphia, PA34 estudios
- Durham, NC33 estudios
- Atlanta, GA31 estudios
- Tampa, FL29 estudios
- Chicago, IL26 estudios
- Portland, OR25 estudios
Otros estudios en Orange
- Cáncer de pulmón de células no pequeñas25 estudios
- Cáncer metastásico20 estudios
- Cáncer del colon y del recto16 estudios
- Cáncer de ovario16 estudios
- Cáncer de páncreas15 estudios
- Melanoma14 estudios
- Cáncer de hígado (carcinoma hepatocelular)14 estudios
- Cáncer de seno14 estudios
- Cáncer de pulmón14 estudios
- Cáncer de próstata14 estudios
- Cáncer de estómago13 estudios
- Cáncer (todos los tipos)13 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.